(Great Neck, N.Y. – April, 02, 2010) — Top line results of an imaging study funded by NARSAD (National Alliance for Research on Schizophrenia and Depression) and Allon Therapeutics showed that 12-week treatment with davunetide, a neuroprotective drug candidate developed by Allon, resulted in a statistically significant increase in levels of a biomarker that is an important indicator of brain cell health………
This study was adapted from Allon Therapeutics Inc.
http://www.narsad.org/?q=node/11269/latest-research
Submitted by Anna
Print 
PDF
Add to Google